免疫检查点抑制剂诱导炎性关节炎。

IF 3.9 4区医学 Q1 MEDICINE, GENERAL & INTERNAL

Clinical Medicine Pub Date : 2025-09-01 Epub Date: 2025-08-06 DOI:10.1016/j.clinme.2025.100496

Benjamin A Fisher, Andrew Allard, Shirish Dubey, Kulveer Mankia, Arthur G Pratt, Lalit Pallan

{"title":"免疫检查点抑制剂诱导炎性关节炎。","authors":"Benjamin A Fisher, Andrew Allard, Shirish Dubey, Kulveer Mankia, Arthur G Pratt, Lalit Pallan","doi":"10.1016/j.clinme.2025.100496","DOIUrl":null,"url":null,"abstract":"Immune checkpoint inhibitors (ICI) used for the treatment of malignancy are associated with immune-related adverse events, which include inflammatory arthritis. ICI-induced inflammatory arthritis (ICI-IA) is a new clinical entity that may lead to functional impairment and may be persistent even after ICI cessation. We discuss the clinical features, investigation and differential diagnosis. Management needs to consider the safety of immunosuppression in the context of the underlying cancer, and current practice will be further informed by ongoing clinical trials.","PeriodicalId":10492,"journal":{"name":"Clinical Medicine","volume":" ","pages":"100496"},"PeriodicalIF":3.9000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12391593/pdf/","citationCount":"0","resultStr":"{\"title\":\"Immune checkpoint inhibitor-induced inflammatory arthritis.\",\"authors\":\"Benjamin A Fisher, Andrew Allard, Shirish Dubey, Kulveer Mankia, Arthur G Pratt, Lalit Pallan\",\"doi\":\"10.1016/j.clinme.2025.100496\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Immune checkpoint inhibitors (ICI) used for the treatment of malignancy are associated with immune-related adverse events, which include inflammatory arthritis. ICI-induced inflammatory arthritis (ICI-IA) is a new clinical entity that may lead to functional impairment and may be persistent even after ICI cessation. We discuss the clinical features, investigation and differential diagnosis. Management needs to consider the safety of immunosuppression in the context of the underlying cancer, and current practice will be further informed by ongoing clinical trials.\",\"PeriodicalId\":10492,\"journal\":{\"name\":\"Clinical Medicine\",\"volume\":\" \",\"pages\":\"100496\"},\"PeriodicalIF\":3.9000,\"publicationDate\":\"2025-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12391593/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.clinme.2025.100496\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/8/6 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.clinme.2025.100496","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/6 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

摘要

用于治疗恶性肿瘤的免疫检查点抑制剂（ICI）与包括炎性关节炎在内的免疫相关不良事件有关。ICI诱导的炎症性关节炎（ICI- ia）是一种新的临床实体，可能导致功能损害，甚至在ICI停止后也可能持续存在。我们讨论临床特征，检查和鉴别诊断。管理人员需要考虑潜在癌症背景下免疫抑制的安全性，目前的实践将通过正在进行的临床试验进一步了解。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Immune checkpoint inhibitor-induced inflammatory arthritis.

查看原文本刊更多论文

Immune checkpoint inhibitor-induced inflammatory arthritis.

Immune checkpoint inhibitors (ICI) used for the treatment of malignancy are associated with immune-related adverse events, which include inflammatory arthritis. ICI-induced inflammatory arthritis (ICI-IA) is a new clinical entity that may lead to functional impairment and may be persistent even after ICI cessation. We discuss the clinical features, investigation and differential diagnosis. Management needs to consider the safety of immunosuppression in the context of the underlying cancer, and current practice will be further informed by ongoing clinical trials.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Clinical Medicine 医学-医学：内科

CiteScore

7.20

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Clinical Medicine is aimed at practising physicians in the UK and overseas and has relevance to all those managing or working within the healthcare sector. Available in print and online, the journal seeks to encourage high standards of medical care by promoting good clinical practice through original research, review and comment. The journal also includes a dedicated continuing medical education (CME) section in each issue. This presents the latest advances in a chosen specialty, with self-assessment questions at the end of each topic enabling CPD accreditation to be acquired. ISSN: 1470-2118 E-ISSN: 1473-4893 Frequency: 6 issues per year